In a report released today, Devin McDermott from Morgan Stanley maintained a Buy rating on Expand Energy, with a price target of $139.00. McDermott......

Exelixis ($EXEL) announced an update on their ongoing clinical study. Exelixis has launched a new Phase 2 trial called “A Phase 2, Single-Arm, Mult......

Exelixis ($EXEL) announced an update on their ongoing clinical study. Exelixis has launched a new Phase 2 trial called “A Phase 2, Single-Arm, Mult......

In a report released yesterday, Pammi Bir from RBC Capital maintained a Buy rating on Extendicare, with a price target of C$38.00. Bir covers the R......

In a report released today, Tom Callaghan from BMO Capital maintained a Buy rating on Extendicare, with a price target of C$38.00. According to Tip......

In a report released today, Tal Woolley from CIBC reiterated a Buy rating on Extendicare, with a price target of C$38.00. Woolley covers the Real E......

In a report released today, Tal Woolley from CIBC reiterated a Buy rating on Extendicare, with a price target of C$38.00. Woolley covers the Real E......

Last week, stocks pushed to fresh highs as strong jobs data and gains in chip stocks helped lift the market. The S&P 500 (SPX) rose 0.84% to 7,397.......

Analysts are intrested in these 5 stocks: ( ($EXE) ), ( ($IP) ), ( ($ESPR) ), ( ($CMPS) ) and ( ($TNXP) ). Here is a breakdown of their recent ...

In a report released yesterday, from Guggenheim maintained a Hold rating on Exelixis. The company’s shares closed yesterday at $48.70. The word on ......